[Latest] Global Hemophilia B Gene Therapy Market Size/Share Worth USD 5,938.5 Billion by 2032 at a 34.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
27 sept. 2023 16h00 HE
|
Custom Market Insights
Austin, TX, USA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Hemophilia B Gene Therapy Market Size, Trends and Insights By Treatment Type...
Exavir Therapeutics announces publication of preclinical data for ultra-long-acting dolutegravir prodrug XVIR-120
09 juin 2022 07h00 HE
|
Exavir Therapeutics
Ultra-long-acting plasma pharmacokinetics and biodistribution to tissues of interest demonstrated in three species Injections were well tolerated with no adverse findings in preliminary toxicology...
Exavir Therapeutics Completes $4M Seed Financing from Key Investors
23 mai 2022 07h00 HE
|
Exavir Therapeutics
NEW YORK and OMAHA, Neb., May 23, 2022 (GLOBE NEWSWIRE) -- Exavir Therapeutics, a company dedicated to transforming the lives of people living with or at risk of acquiring HIV, today announced that...
Ebvia Announces Positive Results Published in Nature for TMPRSS2 Inhibitor for the Prevention and Treatment of COVID-19
29 mars 2022 09h00 HE
|
Ebvia
SAN FRANCISCO, March 29, 2022 (GLOBE NEWSWIRE) -- Ebvia, a biotechnology developing simple-to-use therapeutics for the treatment and prevention of COVID-19, today announces the publication entitled...
Hemophilia Treatment Market worth $16 Billion by 2028, Says Global Market Insights Inc.
01 mars 2022 05h30 HE
|
Global Market Insights Inc.
Selbyville, Delaware, March 01, 2022 (GLOBE NEWSWIRE) -- Hemophilia treatment market revenue is projected to reach USD 16 billion by 2028, according to a new research report by Global Market...
Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral
08 juin 2021 07h00 HE
|
Exavir Therapeutics
With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...
Americans Need COVID Treatment NOW, States the Association of American Physicians & Surgeons (AAPS)
20 oct. 2020 15h55 HE
|
Association of American Physicians and Surgeons
TUCSON, Ariz., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Americans, even one who is as carefully shielded as the President of the United States, continue to be infected with COVID-19. The Association of...
Cidara Therapeutics to Present at Two Upcoming Investor Conferences
24 sept. 2018 16h05 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
Cidara Provides Corporate Update and Reports Second Quarter 2018 Financial Results
08 août 2018 16h30 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results
10 mai 2018 16h05 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...